Teva reorganizes

Share this article:

Teva is undergoing an overhaul as of July 1. Among the changes announced Monday were the creation of a Global Generics Medicines group, which will handle launch and commercialization of its generics portfolio, as well as its over-the-counter business. Former Actavis president Sigurder Olafsson will head this new division.

Additional changes include a new Corporate Development Strategy and Innovation Group, and a new Global Corporate Marketing Excellence and Communications Group.

Teva, which recently found out it will soon navigate a world with generic Copaxone medications, has been facing a series of challenges, including a tumultuous leadership period which capped 2013. The company said in a statement that these changes “are another key step in Teva's strategic direction to create a less complex, integrated company.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.